Bedford Laboratories announced that it
has received approval from the Food and Drug Administration to market
pamidronate disodium for injection. The product will be the only liquid version
available on the market, and is equivalent to the Novartis pamidronate disodium
product (Aredia), a bone resorption inhibitor indicated for the treatment of
hypercalcemia associated with malignancy, for Paget’s disease, and for
osteolytic bone metastases of breast cancer and osteolytic lesions of multiple
"We expect hospitals to appreciate the added convenience
of our presentation, which is a solution, compared to Aredia, which requires
reconstitution," said Tom Murphy, a general manager at Bedford
Laboratories. "Although a solution, it is entirely equivalent in function
to Arediajust easier to use."
Pamidronate disodium injection will be supplied in two
presentations, a 30 mg/10 mL vial and a 90 mg/10 mL vial.